FDA To Review MDS Pharma's Bioequivalence Data From Last Five Years
This article was originally published in The Pink Sheet Daily
Executive Summary
A recent FDA inspection of MDS Pharma Services' Montreal bioanalytical facility has triggered an agency review of all bioequivalence studies conducted at the facility over the last five years. The contract research organization is reviewing its quality assurance practices.